Trials / Terminated
TerminatedNCT02711813
TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of TAB08 in Patients With Systemic Lupus Erythematosus, Not Adequately Controlled With Current Concomitant Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Theramab LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether TAB08 may be beneficial compared to placebo in patients with active Systemic Lupus Erythematosus, not adequately controlled with current concomitant treatment. Secondary purpose is to assess efficacy, safety, pharmacokinetic and pharmacodynamic parameters in this study population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAB08 | biologic |
| OTHER | Placebo |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2016-03-17
- Last updated
- 2018-05-23
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT02711813. Inclusion in this directory is not an endorsement.